Literature DB >> 15273127

In vitro activities of ravuconazole and four other antifungal agents against fluconazole-resistant or -susceptible clinical yeast isolates.

Manuel Cuenca-Estrella1, Alicia Gomez-Lopez, Emilia Mellado, Guillermo Garcia-Effron, Juan L Rodriguez-Tudela.   

Abstract

The activities of ravuconazole and four other antifungal agents were tested against a collection of 1,796 clinical yeast isolates, including fluconazole-susceptible and -resistant strains. Ravuconazole was active against the majority of fluconazole-resistant isolates; but for 102 of 562 (18%) resistant isolates, mainly Candida tropicalis, Candida glabrata, and Cryptococcus neoformans, ravuconazole MICs were > or =1 microg/ml.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15273127      PMCID： PMC478504          DOI： 10.1128/AAC.48.8.3107-3111.2004

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  26 in total

1.  In vitro antifungal susceptibilities of Trichosporon species.

Authors:  Niki I Paphitou; Luis Ostrosky-Zeichner; Victor L Paetznick; Jose R Rodriguez; Enuo Chen; John H Rex
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

2.  Efficacy of ravuconazole (BMS-207147) in a guinea pig model of disseminated aspergillosis.

Authors:  William R Kirkpatrick; Sofia Perea; Brent J Coco; Thomas F Patterson
Journal:  J Antimicrob Chemother       Date:  2002-02       Impact factor: 5.790

3.  Penetration of ravuconazole, a new triazole antifungal, into rat tissues.

Authors:  Hiroshiege Mikamo; Xiang Hua Yin; Yoh Hayasaki; Yoshiko Shimamura; Keizo Uesugi; Nobuyuki Fukayama; Masaru Satoh; Teruhiko Tamaya
Journal:  Chemotherapy       Date:  2002-03       Impact factor: 2.544

4.  Effect of ravuconazole, a new triazole antifungal, in a rat intraabdominal abscess model.

Authors:  H Mikamo; X H Yin; Y Hayasaki; M Satoh; T Tamaya
Journal:  Chemotherapy       Date:  2001 Sep-Oct       Impact factor: 2.544

5.  In vitro activities of ravuconazole and voriconazole compared with those of four approved systemic antifungal agents against 6,970 clinical isolates of Candida spp.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones; D J Diekema
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

Review 6.  Novel triazole antifungal agents.

Authors:  H L Hoffman; E J Ernst; M E Klepser
Journal:  Expert Opin Investig Drugs       Date:  2000-03       Impact factor: 6.206

7.  Efficacy of ravuconazole in treatment of systemic murine histoplasmosis.

Authors:  K V Clemons; M Martinez; L Calderon; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2002-03       Impact factor: 5.191

8.  Efficacy of ravuconazole in treatment of mucosal candidosis in SCID mice.

Authors:  K V Clemons; D A Stevens
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

9.  Antifungal activities of posaconazole, ravuconazole, and voriconazole compared to those of itraconazole and amphotericin B against 239 clinical isolates of Aspergillus spp. and other filamentous fungi: report from SENTRY Antimicrobial Surveillance Program, 2000.

Authors:  M A Pfaller; S A Messer; R J Hollis; R N Jones
Journal:  Antimicrob Agents Chemother       Date:  2002-04       Impact factor: 5.191

10.  In vitro activity of a new oral triazole, BMS-207147 (ER-30346)

Authors:  J C Fung-Tomc; E Huczko; B Minassian; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1998-02       Impact factor: 5.191
View more
  9 in total

1.  In vitro activity of ravuconazole against 923 clinical isolates of nondermatophyte filamentous fungi.

Authors:  Manuel Cuenca-Estrella; Alicia Gomez-Lopez; Emilia Mellado; Guillermo Garcia-Effron; Araceli Monzon; Juan Luis Rodriguez-Tudela
Journal:  Antimicrob Agents Chemother       Date:  2005-12       Impact factor: 5.191

2.  Molecular mechanisms of drug resistance in clinical Candida species isolated from Tunisian hospitals.

Authors:  Jamel Eddouzi; Josie E Parker; Luis A Vale-Silva; Alix Coste; Françoise Ischer; Steve Kelly; Mohamed Manai; Dominique Sanglard
Journal:  Antimicrob Agents Chemother       Date:  2013-04-29       Impact factor: 5.191

3.  Isolation of Cryptococcus laurentii from Canada Goose guano in rural upstate New York.

Authors:  Tera Filion; Sarah Kidd; Karen Aguirre
Journal:  Mycopathologia       Date:  2006-11       Impact factor: 2.574

4.  Subcutaneous cryptococcosis due to Cryptococcus diffluens in a patient with sporotrichoid lesions case report, features of the case isolate and in vitro antifungal susceptibilities.

Authors:  A Serda Kantarcioğlu; Teun Boekhout; G Sybren De Hoog; Bart Theelen; Ayhan Yücel; Tuba R Ekmekci; Bettina C Fries; Reiko Ikeda; Adem Koslu; Kemal Altas
Journal:  Med Mycol       Date:  2007-03       Impact factor: 4.076

5.  Effect of Candida glabrata FKS1 and FKS2 mutations on echinocandin sensitivity and kinetics of 1,3-beta-D-glucan synthase: implication for the existing susceptibility breakpoint.

Authors:  Guillermo Garcia-Effron; Samuel Lee; Steven Park; John D Cleary; David S Perlin
Journal:  Antimicrob Agents Chemother       Date:  2009-06-22       Impact factor: 5.191

6.  Efficacy and safety of fosravuconazole L-lysine ethanolate, a novel oral triazole antifungal agent, for the treatment of onychomycosis: A multicenter, double-blind, randomized phase III study.

Authors:  Shinichi Watanabe; Ichiro Tsubouchi; Akihiro Okubo
Journal:  J Dermatol       Date:  2018-08-29       Impact factor: 4.005

7.  Screening the pandemic response box identified benzimidazole carbamates, Olorofim and ravuconazole as promising drug candidates for the treatment of eumycetoma.

Authors:  Wilson Lim; Bertrand Nyuykonge; Kimberly Eadie; Mickey Konings; Juli Smeets; Ahmed Fahal; Alexandro Bonifaz; Matthew Todd; Benjamin Perry; Kirandeep Samby; Jeremy Burrows; Annelies Verbon; Wendy van de Sande
Journal:  PLoS Negl Trop Dis       Date:  2022-02-04

Review 8.  Clinical Pharmacokinetics of Second-Generation Triazoles for the Treatment of Invasive Aspergillosis and Candidiasis.

Authors:  Zorica Jović; Slobodan M Janković; Dejana Ružić Zečević; Dragan Milovanović; Srđan Stefanović; Marko Folić; Jasmina Milovanović; Marina Kostić
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2019-04       Impact factor: 2.569

9.  Voriconazole in the management of nosocomial invasive fungal infections.

Authors:  Javier Pemán; Miguel Salavert; Emilia Cantón; Isidro Jarque; Eva Romá; Rafael Zaragoza; Angel Viudes; Miguel Gobernado
Journal:  Ther Clin Risk Manag       Date:  2006-06       Impact factor: 2.423
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.